SenzaGen AB aksje

SenzaGen AB provides non-animal tests for assessing allergenicity. The company offers GARD skin OECD 442E, GARD skin dose-response, GARD skin medical device; and GARD air, a respiratory sensitization assessment. It also provides biological evaluation, in vitro biocompatibility testing, cytotoxicity, irritation, and skin sensitization medical device services; advisory services for medical devices; and substance based medical devices. In addition, the company offers regulatory toxicity testing services, including skin corrosion, skin irritation, skin sensitization, and skin absorption; and eye irritation, phototoxicity, and cytotoxicity testing services and advisory services to pharma, medial devices, cosmetics, an chemical industries. Further, it provides SenzaGen, a test portfolio to assess toxicity of chemicals, cosmetics, medical devices, drug candidates, and nutrition/food additives.The company offers services through license partners and distributors. It has a collaboration agreement with the Research Institute for Fragrance Materials to develop tests for photosensitization. SenzaGen AB was incorporated in 2010 and is headquartered in Lund, Sweden.